Participant flow

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) · Source last updated 2026-09-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive afatinib dimaleate 40mg PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Afatinib Dimaleate: Given PO

   id

   FG000

   title

   Treatment (Afatinib Dimaleate)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Never Started Treatment

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Adverse Event

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Death

   5. reasons

      1. group Id

         FG000

         num Subjects

         27

      type

      Disease Progression

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Alternative Therapy

   7. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Increased Tumor Burden

   8. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Symptomatic Detrioration

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         39

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         37

      comment

      One patient ineligible, 2 patients never started treatment. This is the primary analysis population.

      type

      Eligible and Started Protocol Therapy

   4. achievements

      1. group Id

         FG000

         num Subjects

         37

      comment

      Excluding two who did not receive afatinib treatment and one who was not assessed for toxicity

      type

      Reported Adverse Events Data

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      comment

      Treatment continued until disease progression or intolerability.

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

To be assigned to a specific MATCH subprotocol, patients needed to submit a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial entered corresponding MATCH subprotocol. For the subprotocol B, patients had to have a qualifying ERBB2 actionable mutation.

recruitment Details

Subprotocol B was activated on August 12, 2015. Fifty-nine patients were assigned to Subprotocol B after screening, all from screening cohort. Of the 59 patients, 40 patients were enrolled in arm B between August 2015 and June 2017.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice